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Abstract
Myeloid cells are effectors of both anti-tumor and pro-tumor immune responses, but much needs to be determined as to signals that determine which function of the myeloid lineage dominates. Shown here, mice with myeloid-specific IKKβ loss exhibit more rapid growth of cutaneous and lung melanoma tumors. 
Specifically, in a BRAF

INTRODUCTION
Malignant melanoma is a lethal disease due to its aggressive capacity for metastasis and resistance to therapy. For decades considerable effort has gone toward development of immunotherapy for treatment of metastatic melanoma. Tumors can potentially be recognized as 'altered self', akin to allogeneic immunity, and leading to an anti-tumor immune response of potential value in the adjuvant setting. This motivated investigations of interactions between melanoma and immune cells and translation of this knowledge into effective clinical strategies. The majority of the early studies strove to increase T cell responses to the tumor partly through manipulation of dendritic cells (DCs), a key antigen presenting cell (APC) type. However, macrophages and neutrophils were also found to be key mediators of inflammation and immunity in cancer.
Their phenotypes depend on the physiological or pathological milieu in which they reside. Pro-tumor macrophages (M2) and neutrophils (N2) can be contrasted with the classically activated macrophages (M1) and neutrophils (N1) that present antigen and/or produce reactive oxygen species (ROS) involved in the killing of foreign organisms and tumor cells (1, 2) . Moreover, the cytokines and chemokines produced by myeloid cells can significantly affect DC and the Th1 (anti-tumor) versus Th2 (pro-tumor) skew of the immune cells in the tumor microenvironment (TME).
Nuclear factor-kappa B (NF-κB) is a ubiquitous transcription factor that regulates expression of proinflammatory genes, playing a crucial role in immune response (3) . NF-κB activation is regulated by the IκB kinase complex (IKKα, IKKβ, NEMO) which has become a major target for anti-inflammation and cancer therapy (4) (5) (6) . Considering the importance of IKK, particularly IKKβ, in tumor immunity, a myriad of efforts have focused on the molecular mechanism for IKKβ regulation of the myeloid-mediated immune response during tumor development. Deletion of the Ikkβ gene in myeloid cells led to inhibition of colitis-induced colon cancer(7) and expression of an IκB-super repressor in resident macrophages (Kupffer cells) inhibited progression of hepatocellular carcinoma (8) . Furthermore, introduction of NF-κB deficient macrophages into mice with early ovarian cancer lesions slowed cancer progression (9) . Despite these indications of a protumorigenic role of NF-κB in macrophages, other reports indicate that NF-κB is needed for the anti-tumorigenic function of macrophages in breast cancer metastasis and angiosarcoma (10, 11 
MATERIALS AND METHODS
Myeloid Ikkβ knockout models and melanoma metastatic models
All animal experiments were approved by the Vanderbilt University Institutional Animal Care and Use
Committee. To knockout Ikkβ in myeloid cells in either C57BL6 or FVB strain mice, LysM-Cre mice with Crerecombinase expressed under the control of the murine lysozyme M gene regulatory region (1) were bred with Ikkβ f/f mice (2) . The C57Bl/6 mice IKKβ f/f mice were back-crossed from FVB to C57BL/6 five generations.
These mice were then bred to mice harboring the loxP-flanked tdTomato (mT) following the EGFP (mG) Mouse blood was isolated as previously described (12) . Cells were cultured in OptiMEM with 0.5% FBS. Macrophages were depleted in vivo by intravenous injections of clodronate or liposome vehicle followed by intraperitoneal injection of 1X10 6 melanoma cells, depletion was validated, and effects on tumor growth were scored as described in Supplemental Methods. To evaluate the effect of macrophage depletion on tumor growth, clodronate or liposome vehicle were injected into mice 1 day prior to and every other day after implantation of 10 6 tumor cells, continuing throughout the experiment.
As detailed in Supplemental Methods, CD8+ T cells or neutrophils were depleted using injections of mAb or isotype control for 3 days prior to implanting with melanoma cells, with injections every other day thereafter. Systemic depletion of these leukocytes in bone marrow was evaluated at the study endpoint using flow cytometry.
Immunocytochemistry, Immunohistochemistry, Cytokine Array and ELISA
Immunostaining was performed according to the previously described protocol(5), using antibodies against S-100 and MART1. Inflammatory Cytokine Arrays and ELISA were performed as described previously(5).
Tetramer Assay
A single cell suspension was prepared from lung tumor tissues. H-2K(b) monomer loaded with SVYDFFVWL (TRP2) peptide was provided by the NIH Tetramer Core Facility and tetramerized using APClabeled streptavidin. Cells were stained with PerCP-Cy5.5-conjugated anti-CD8 antibody and fluorescent TRP2 tetramer. The TRP2-tetramer positive CD8+T cells were enumerated by flow cytometry( see Supplemental Methods for additional details).
Statistics
Data are expressed as mean ± SEM; the unpaired, 2-tailed Student's t test was used to determine P values as detailed in Supplemental Methods. P <0.05 were considered significant. 
RESULTS
Myeloid IKKβ is essential for anti-tumorigenic immunity
C57/BL6 and FVB mice with targeted deletion of Ikkβ in myeloid cells (Ikkβ
MyeΔ/Δ
) were generated by efficient Cre-loxP-mediated recombination in macrophages and neutrophils, but not in T cells or in the majority of B cells and DCs (Fig. 1A) (11, 13 
The macrophage is a key mediator in anti-tumor immunity
We sought first to explore whether macrophages might influence anti-melanoma immunity using a peritoneal tumor cell recruitment assay. These analyses revealed that there were progressive increases in leukocytes and decreases in tumor cells in the peritoneum (Fig.2A) (Fig.2D) . In contrast, when neutrophils were depleted in Ikkβ WT mice using anti-Ly6G antibody (Fig.S2C ) there was only a 6-fold increase in Gluc reporter activity in lung, indicating enhanced melanoma growth in the lung of neutrophil-depleted mice (Fig.S2D, 6 ,769±4085 vs. 1131±344 p<0.05, n=5). We conclude that both macrophages and neutrophils lead to inhibition of melanoma tumor growth, but macrophages have a much more striking effect (439-vs 6-fold increases in tumor size after macrophage depletion vs neutrophil depletion).
NF-κB modulates macrophage-mediated tumor cell death
To determine whether defects in macrophage tumor cell killing and phagocytosis were responsible for the increased tumor growth in the Ikkβ MyeΔ/Δ mice, we co-cultured macrophages with RFP-tagged tumor cells. In contrast to Ikkβ WT macrophages (Fig.3A) , Ikkβ MyeΔ/Δ macrophages exhibited poor phagocytic activity toward RFP-tagged Braf V600E /Pten -/-melanoma cells based on uptake of RFP (Fig.3B) (Fig.3C ). This result was confirmed by latex bead assays that found the efficiency of macrophage phagocytosis was significantly reduced upon loss of IKKβ (Fig.S3C) . However, when cell-cell interaction was observed after prolonged culture(3 days), IKKβ Δ/Δ macrophages did eventually engulf tumor cells, though engulfed tumor cells 
appeared not to undergo digestion (Fig.S3B) To test the role of CTL directly, CD8 + T cells were depleted using CD8-YTS antibody to achieve 98.4% CD8 + T cell depletion (Fig.S4D) . In contrast to control mice that completely rejected melanoma formation after input of Gluc-Braf 
NF-κB is required for cytokine-mediated immunity
To learn whether myeloid IKKβ deletion leads to any alteration in cytokine profiles in vivo, which might affect the Th1-versus Th2-skew of immune cells, sera from non-tumor bearing Ikkβ WT What might be clinical meanings of these findings in melanoma patients? To explore the potential relevance of these findings in human melanoma, we evaluated CCL-11 expression in macrophages(CD163+) of biopsy specimens from 6 melanoma patients before and after treatment with the proteasome inhibitor, bortezomib (VELCADE), and temozolomide in a phase I/II clinical trial (24) . VELCADE, an FDA-approved agent in some cancers, inhibits degradation of phosphorylated-IκB, thus reducing NF-κB activity by retaining RelA/p65 in the cytoplasm, but also impacts a number of additional pathways (25) (26) (27) (28) .
Tissues were stained for macrophages (CD163 ) (29) , phospho-RelA(p65), activated CD8 + T cells (CD107a), and CCL-11, visualized by confocal microscopy, and quantitated using Metamorph (Fig.S6A&B) . Treatment resulted in a small but significant reduction in nuclear phospho-REL-A/p65 (29,586±2,741 vs. 33,462±3,460, p<0.01) (Fig. 6A) , a 17% up-regulation of CCL11(36,772±1,860 vs. 31,452±2,224, p<0.01) (Fig.6B) , and a (Fig.S6 E&F) was significantly reduced. Thus, our findings both suggest that systemic therapy with VELCADE may act via NF-κB to change chemokine expression and CTL effector activity in cancer patients, and that targeting NF-κB signaling in human melanoma risks negatively impacting anti-tumor immunity. 
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